Pfizer Taps Chai Discovery to Fast-Track AI-Designed Biologics
Chai Discovery announced a license with Pfizer to deploy its frontier AI platform, including the Chai-3 model and a Pfizer-custom model, within Pfizer’s drug discovery engine to accelerate biomolecule design and target hard-to-reach areas. Pfizer will gain early access to Chai-3, which advances antibody design and generalization, alongside a tailored model leveraging Pfizer’s data. The deal highlights growing use of AI in pharma to shorten discovery timelines that traditionally span months to weeks.